A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

Jeffrey J. Raizer, Sean Grimm, Marc C. Chamberlain, M. Kelly Nicholas, James P. Chandler, Kenji Muro, Steven Dubner, Alfred W. Rademaker, Jaclyn Renfrow, Markus Bredel

Research output: Contribution to journalArticlepeer-review

128 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas'. Together they form a unique fingerprint.

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience